Category: Corona Virus

Page 338«..1020..337338339340..350360..»

Coronavirus tally: Daily hospitalizations and deaths keep climbing, as cases rise to top of recent range – MarketWatch

June 30, 2022

While health regulators debated over how to proceed with developing new booster shots, COVID-19-related hospitalizations and deaths have quietly climbed to new multi-month highs as cases bump up against the top of a six-week range. The seven-day average of new cases rose 7% from two weeks ago to 112,464 on Wednesday, according to a New York Times tracker. The highest reading over the past six weeks was 112,797 on June 7. Big increases in the South, with Arkansas, Mississippi and Alabama seeing cases surge more than 50% in two weeks, offset declines in most Northeast states. The daily average for hospitalizations, which has been rising every day since April 18, rose 9% from two weeks ago to 32,706 on Wednesday, the most since March 9. The daily average for deaths jumped 18% from two weeks ago to 388, the most since April 19.

Read more here:

Coronavirus tally: Daily hospitalizations and deaths keep climbing, as cases rise to top of recent range - MarketWatch

Assessing the HIV Community’s Needs and Concerns About Long COVID – POZ

June 30, 2022

COVID-19 and long COVID continue to impact peoples lives, including those of people living with HIV. A recent survey, report and webinar assessed the HIV communitys concerns regarding COVID-19 and offered community leaders recommendations for meeting the needs of the HIV population at this moment in history.

Titled Resourcing the HIV Community to Face COVID and Long COVID in 2022, the report and webinar were presented by Strategies for High Impact, the Network for Long COVID Justice and Springboard Health Lab.

According to the report, the top-line recommendations are that the HIV sector should be resourced to:

For the report, researchers conducted a digital survey between January and March, which drew 71 participants, 70.4% of whom reported that they were living with HIV.

Participants reported significant pandemic stress, states the report, including concerns about long COVID (88.7%), the impact of COVID-19 infections in people living with HIV (89.9%), risks to HIV programs and funding (73.2%), increased stigma around viral infections (70.4%) and the impact of isolation on PLHIV (88.7%).

The report includes several video segments, such as the testimony below from Philip Shubin about living with HIV and long COVID:

The report concludes that HIV communities have a widespread need and eagerness for information, resources and support on a range of issues and concerns about COVID-19 and long COVID. These include:

The HIV sector has much to teach our nation about tackling pandemicsincluding the importance of meaningful involvement of those most affected, wrote the authors in the reports introduction, adding that increasing evidence indicates that PLHIV may be at significantly higher risk of long COVID.

The report highlights the racial disparities that persist in both health crises, stating: As the nation reaches the tragic marker of 1 million documented deaths from COVID-19, it is clear that the tragic losses of the pandemic have occurredand continue to occurmuch more heavily in the Black and Brown communities that also face disproportionate HIV rates.

To learn more about these intersections and disparities, read the full report or join a live Zoom discussion about it on Thursday, July 14, at 3 p.m.

To learn more about the coronavirus and HIV, click #COVID-19. Youll find articles such as The HIV Movement Must Come Through, an opinion piece by HIV activist JD Davids, who outlines how people with HIV can be good allies to those with long COVID. Davids also lists resources for those with long COVID. For more about the pandemic, visit POZs sister website COVIDHealth.com.

Read the original here:

Assessing the HIV Community's Needs and Concerns About Long COVID - POZ

Covid-19 Updates: Vaccines, Variants and Omicron News – The New York Times

June 28, 2022

A healthcare worker prepares a Pfizer-BioNTech coronavirus booster shot in Los Angeles earlier this year.Credit...Caroline Brehman/EPA, via Shutterstock

An expert committee recommended Tuesday that the Food and Drug Administration plan on an updated booster shot of the coronavirus vaccines that targets some form of the Omicron variant that has dominated for months.

The panels 19-2 vote paves the way for F.D.A. regulators to recommend a new formulation for the boosters that the Biden administration hopes to offer later this year, before an expected winter resurgence of the virus.

The committee debated but did not specify which formulation might work best. The F.D.A. appeared to be leaning toward a combination of the existing vaccine and two subvariants of Omicron, known as BA.4 and BA.5. According to new estimates from the Centers for Disease Control and Prevention, those two subvariants together now make up more than half of new cases in the country.

Dr. Peter Marks, who oversees the F.D.A.s vaccine division, displayed a timeline suggesting that regulators would decide on a new vaccine composition by early July, and that a fall booster campaign could begin in October. Manufacturers of the mRNA vaccines, made by Moderna and Pfizer-BioNTech, require roughly three months to begin producing doses with a new composition.

Clinical trial results on a combination of the so-called prototype, or existing, vaccines and Omicron itself have received mixed reviews so far. In briefing materials, regulators suggested that such a design is already somewhat outdated.

The panel struggled with what one member called trying to predict the future of where the virus is headed. Another panelist called the data uncomfortably scant.

Dr. Adam C. Berger, a National Institutes of Health official, said he supported an updated booster in theory, but Im not sure that we have evidence to support a change necessarily today. Other members said the most impressive booster might be one proposed by Novavax, a company whose vaccine is not yet even available as initial doses in the United States.

But more members of the panel seemed convinced that an updated booster was needed. Were all troubled by the steady erosion of immune protection, Dr. Mark Sawyer, an infectious disease specialist at Rady Childrens Hospital in San Diego, said. Were going to be behind the eight ball if we wait longer.

The panel seemed generally against switching the vaccine formulation for people who have not yet been fully vaccinated.

I dont think we should lose the prototype. I think its a known entity and its doing really well in its current job, Dr. Amanda Cohn, a top C.D.C. official, said.

There was little talk about any variant other than Omicron, which has proved to be a global game-changer, dulling vaccine-induced protection and spawning even more wily forms of the virus with the power to reinfect people. Dr. Marks said figuring out how to counter the viruss shifts was science at its hardest.

Dr. Jerry Weir, an F.D.A. official, said that forms of Omicron have dominated for about six months now and whatever form of the virus is circulating in the fall is more likely to be tied to the Omicron family than earlier versions of the virus.

Overall, he said, the data indicate that a booster that incorporates an Omicron component produces a better antibody response against that family and offers the potential for improved vaccine effectiveness.

Several committee members cautioned against holding out for more definitive data. Dr. Melinda Wharton, a C.D.C. vaccine specialist, said she was convinced that a booster aiming at some form of Omicron would increase the breadth of immunity, as an adviser to the World Health Organization suggested.

Members of the panel largely skirted the question of who should receive a new booster. Some have suggested that a fall booster will be broadly necessary, while others contend that because the current vaccines protection has held up against severe disease, the next round of shots should be limited to the elderly and high-risk individuals.

Although the overall death rate is low now compared to earlier in the pandemic, C.D.C. officials said Americans 70 and older have driven increases in hospitalizations. Heather Scobie, an agency epidemiologist, said that despite rather poor uptake, second boosters were reducing the risk of death in older adults.

Federal health officials have suggested for months that more advanced vaccines may be needed to combat the rapidly evolving virus, warning that vaccine-induced protection against infection has faded, allowing some Americans to be reinfected even in the span of several months.

In briefing materials, F.D.A. officials said the risk of another major outbreak will rise later this year due to the combination of waning immunity, further evolution of variants, and increased indoor activity.

Moderna and Pfizer, the makers of the two most widely-used vaccines in the United States, have both studied vaccines that target the first version of Omicron, expecting them to be seriously considered as the fall booster option. But the research has been complicated by the subvariants, for which neither company has developed shots yet. If the F.D.A. chooses a vaccine that targets BA.4 or BA.5, it is unclear whether either company will be able to study it and manufacture doses in time for a fall booster campaign.

Pfizer presented the only data on such a formulation preliminary data from a mouse trial suggesting it worked better against all Omicrons subvariants than the existing vaccine does. But a company official said researchers do not yet have a side-by-side comparison with a version targeting Omicron itself.

More here:

Covid-19 Updates: Vaccines, Variants and Omicron News - The New York Times

Coronavirus Omicron variant, vaccine, and case numbers in the United States: June 27, 2022 – Medical Economics

June 28, 2022

Total vaccine doses distributed: 762,236,905

Patients whove received the first dose: 259,426,758

Patients whove received the second dose: 222,123,223

% of population fully vaccinated (both doses, not including boosters): 66.9%

% tied to Omicron variant: 100%

% tied to Other: 0%

View original post here:

Coronavirus Omicron variant, vaccine, and case numbers in the United States: June 27, 2022 - Medical Economics

Coronavirus: Experiencing THIS symptom when you visit the toilet could be an early sign of COVID-19 – Times of India

June 28, 2022

COVID-19 is not just a respiratory illness, rather it can affect several other parts of the body. From the brain to the heart to the kidneys, the SARs-CoV-2 virus can negatively impact major human organs. However, one major problem that has been reported time and again is digestive issues associated with coronavirus.

As per a review study from September 2020, 53% of people hospitalized with COVID-19 experienced at least one gastrointestinal (GI) symptom during their illness.

According to a clinical update that appeared in The American Journal of Emergency Medicine in January 2022, "[GI] symptoms are common, with up to one-third of patients with COVID-19 presenting first with GI symptoms. Nausea and vomiting may be present in up to two-thirds of patients with COVID-19. Approximately 40% of patients with COVID-19 will have loss of appetite, and up to 50% will have diarrhea. Abdominal pain is less common, occurring in less than 10%.

That said, it is important to recognize the symptoms before the virus takes a severe toll on our body.

Also read: Vitamin D3 and B12 deficiency is a silent epidemic; linked to your immune system, brain and hormonal health

Read the original post:

Coronavirus: Experiencing THIS symptom when you visit the toilet could be an early sign of COVID-19 - Times of India

The Omicron subvariants BA.4 and BA.5 have together become dominant in the U.S., the C.D.C. estimates. – The New York Times

June 28, 2022

Continuing their rapid march across the United States, the Omicron subvariants known as BA.4 and BA.5 have together become dominant among new coronavirus cases, according to new estimates on Tuesday from the Centers for Disease Control and Prevention.

As of the week ending Saturday, BA.4 made up 15.7 percent of new cases, and BA.5 was 36.6 percent, accounting for about 52 percent of new cases in the United States, numbers that experts said should rise in the weeks to come.

The statistics, released Tuesday morning, are based on modeling and can be revised as more data comes in, which happened in late December, when the agencys estimates missed the mark.

In the less than six months since BA.4 and BA.5 were first detected in South Africa, the two subvariants appeared in the United States to be overtaking two earlier Omicron subvariants, including BA.2, which was the prevailing version for a time earlier this spring. The other, BA.2.12.1, was dominant alone as of the week ending June 18, according to C.D.C. estimates. Over the winter, the form of Omicron that first emerged in the United States sent case counts soaring. Before that, the Delta variant had been dominant in the United States since early summer.

BA.4 and BA.5 exhibit the qualities of escape artists, able to elude some of the antibodies produced after coronavirus vaccinations and infections, including infections caused by some earlier versions of Omicron. That may explain why these subvariants have spread even faster than others in the Omicron family. But there is not yet much evidence that they cause more severe disease.

The BA.4 and BA.5 subvariants have been detected throughout the world, and they fueled a surge of cases in South Africa in the spring, despite widespread pre-existing immunity to the virus. The wave was not as high as South Africas earlier waves, and deaths did not rise as sharply. Just last week, South Africa repealed its rules that required masks in indoor public spaces.

In recent weeks, more than 100,000 new coronavirus cases have been reported each day on average in the United States, according to a New York Times database, a figure that captures only a portion of the true number. Many infections go uncounted in official reports. Some scientists estimate that the current wave of cases is the second-largest of the pandemic.

As of Monday, hospitalizations in the United States were up 6 percent in the last two weeks, to an average of more than 31,000 each day, according to federal data. New deaths have stayed below 400 per day on average, data from state and local health agencies show. That is a fraction of the thousands seen daily during the winter Omicron peak.

But in my mind, 250 deaths a day is still too many, Dr. Rochelle Walensky, the C.D.C. director, said last week in Aspen, Colo. The deaths that were seeing are generally among people who are either elderly, frail, many comorbidities, whove had a lot of vaccine shots or people who are unvaccinated.

Many Americans with risk factors have said that they feel ignored and abandoned as their governments and neighbors have sought a return to normal.

As always, the spread of the virus is a regional affair. In the Northeast and Midwest, known cases have been declining for weeks, while in the South and West, cases are increasing.

Across the nation, public health rules continue to be lifted, including the ending on Saturday of an indoor mask mandate for Alameda County, the San Francisco Bay Areas second-most populous county. In New York City, Broadway theaters save for one are retiring their mask requirements beginning Friday. Even the longstanding requirement to test for the coronavirus before flying to the United States from abroad was dropped this month.

While the recent availability of vaccines for children ages 6 months to 5 years was a welcome development for many parents and day care centers, experts do not expect the availability of pediatric doses to change the overall trajectory of the pandemic in the United States.

The natural waning of vaccine protection against infection over time, along with the immune evasiveness of BA.4 and BA.5, might explain why these subvariants have been able to spread quickly. It has also lent urgency to the development of Omicron-targeted boosters. While vaccine manufacturers have raced to develop these, they are based on other versions of Omicron, and it was not yet clear how well they could protect against infection with BA.4 and BA.5.

Preliminary evidence from laboratory research suggests that unvaccinated people who were infected with the original version of Omicron, known as BA.1, might be easily reinfected by BA.4 or BA.5. Vaccinated people are likely to fare somewhat better, the study suggests.

But as the virus evolves, no one can tell whether retooled vaccines could become outdated by the time they become available.

What we dont know is whats going to happen with a new vaccine in the fall, Dr. Walensky said while in Aspen. I do think were going to need more vaccines.

Originally posted here:

The Omicron subvariants BA.4 and BA.5 have together become dominant in the U.S., the C.D.C. estimates. - The New York Times

MSU researchers use AI to stay ahead of COVID-19 and other diseases – MSUToday

June 28, 2022

Although vaccines and treatments are now available that didnt exist when the U.S. first declared a public health emergency in response to the novel coronavirus, the virus is still out there evolving. In fact, our immune responses are naturally influencing the trajectory of that evolution.

Thinking in terms of survival of the fittest, a virus that can evade vaccines or natural immunity will be more fit than its predecessor, Wei said. That means it will be better equipped to survive, multiply and infect others. The take-home message isnt that people shouldnt protect themselves, Wei said, but that a virus that still infects about 100,000 Americans daily isnt going to get tired, bored or just give up.

Viruses dont have a personality. They just survive, Wei said. We want to make sure we are prepared.

Spartan researchers are bringing the power of mathematics, computation and artificial intelligence to bear in the effort to prepare for evolving infectious viruses. Credit: Gerd Altmann/Pixabay

This new grant, funded by the National Institute of Allergy and Infectious Diseases, is an investment to improve our readiness through cutting-edge technology. But it also leverages the expertise and experience of Wei and Zheng.

Zheng has led NIH-funded grants for two decades, although this will be his first with an explicit focus on the coronavirus.

Im very proud that this is the first one, he said. But we dont want it to be the last. This new grant will expand my labs capacity to accommodate more needs campuswide and we want to use that to stimulate more collaboration.

Zheng brings a unique virology skillset to MSU. He first was recruited in 2005 as an HIV researcher and, over time, his lab has grown to study the molecular biology of influenza and Ebola. When the coronavirus pandemic struck, he knew his team could provide valuable experimental infrastructure to help better study the new virus.

For example, his team developed less dangerous versions of the virus along with lab-grown cells for these pseudo-viruses to infect while preserving the biochemistry of real, clinical infections. The researchers also created very sensitive assays, or tests, that would reveal which viruses infected which cells. All of this provided researchers safer, faster and easier ways to study a complex virus while generating valuable biological data.

Similarly, in early 2020, Weis team started putting its unique skills to work combatting the coronavirus.

Before the pandemic, we had had success in worldwide competitions, being recognized as one of the top labs in combining AI and mathematics for drug discovery, said Wei, who also holds an appointment in the Department of Electrical and Computer Engineering in the College of Engineering.

Weis research had focused on using AI to help design new pharmaceuticals in partnership with Pfizer and Bristol-Myers Squibb. Within days of Chinas Wuhan lockdown in January 2020, Weis team started sharing its AI resources to help find drugs to fight the coronavirus and reveal new potential drug targets. But the researchers also recognized their algorithms could do more.

With a global community working to fight the coronavirus, there was a wealth of new genomic data describing the virus being shared regularly. Wei and his team saw an opportunity to combine that data with their AI framework to understand how the virus was mutating as time went on.

For example, they were among the first to see how survival of the fittest was playing out in the virus and steering its evolution, Wei said. His team then used that knowledge to look ahead and identify two potentially vital sites on the viruss spike protein, the protein the virus uses to latch onto cells and infect them. Mutations in those two spike protein sites would later turn out to play crucial roles in the viruss most prevalent variants, Wei said.

We took what we were doing with deep learning and mathematics, then combined that with the viral genomic data to understand the evolution of the virus, look at its trajectory and ask whats going to happen, Wei said. That gives us a way to predict what can happen in the future.

Wei and Zheng have been collaborating for about a year, starting before the grant was awarded. Their teamwork has informed precise algorithms with real-world data and provided real experimental results to compare with AI predictions.

We need to have that interdisciplinary collaboration for this to work, Zheng said. Everything the computer models predicted, we had to confirm with experiments in a living system.

Although Weis team validated its AI with laboratory experiments, the researchers still knew theyd need to prove their algorithms could work with a brand-new variant with very little data. Then, in the fall of 2021, the first omicron variant appeared.

Back in late November, people didnt know what was going to happen, Wei said.

Researchers and public health officials responded immediately, but the process of experimenting and gathering data takes weeks. Meanwhile, Weis team put its AI to the test.

Their projections showed this first iteration of omicron would be more infectious, better at eluding the protection of vaccines and less responsive to antibody treatments than earlier variants.

Within days, we had our predictions, Wei said. A month and a half later, everything we predicted proved to be true by experimental labs around the world. Using AI, we can give people a month or two to prepare.

Then, in early 2022, a new subvariant of omicron called BA.2 started spreading. A similar scenario played out. Weis team predicted it would be more infective and even more elusive, which would allow it to become the next dominant variant.

We made our predictions on February 11, and on March 26, the World Health Organization announced it was the dominant form of the virus, Wei said.

Now that scientists and officials better understand omicron, the newer versions arent garnering the same level of attention as their predecessors. But new variants and subvariants are still emerging. With support from the National Institutes of Health, the MSU team is working to ensure we stay prepared for whats next, whether thats a new variant, something more familiar like the flu or something entirely different.

Read more here:

MSU researchers use AI to stay ahead of COVID-19 and other diseases - MSUToday

Coronavirus cases on the rise once again – KAMR – MyHighPlains.com

June 28, 2022

AMARILLO, Texas (KAMR/KCIT) COVID-19 cases are rising across the Amarillo area, Texas, and the nation.

The city of Amarillo is seeing more than 800 more active cases than we had this time last month.

Dr. Rodney Young, Regional Chair of Family & Community Medicine at the Texas Tech University Health Sciences Center said what is causing the rise in new cases is a new subvariant.

It started with the Omicron, then with the BA.2 and now there is a subvariant of BA.2, said Dr. Young.

He said cases are likely to continue to rise as July 4th draws near and families gather.

When you have occasions to gather, that is the way it spreads very easily person to person, said Dr. Young.

Dr. Young added as cases do continue to rise, an upside is that they have not seen a rise in hospitalization the way they did in the earlier stages of the pandemic.

He said patients with the subvariant are not presenting with severe COVID-19 symptoms, some are presenting with a little cough, runny nose, and watery eyes.

A number of the cases that we are diagnosing now that werent COVID a few weeks ago, tend to be folks they are feeling like they are having flares in allergy symptoms or cold type symptoms, said Dr. Young.

Dr. Young said that those who are vaccinated and who get subvariant COVID illnesses are less likely to get less severe forms of the illness or experience long covid.

Dr. Young added the virus is here to stay and it will always be a part of the disease landscape to some extent and added what the medical community hopes to happen is that it moves from a pandemic to an endemic.

Some years or some times are worse than others, but hopefully there is enough immunity around and enough measures that we can take to help mitigate the spread within a community, said Dr. Young.

Dr. Young said he doesnt have an exact answer to when that could happen, but he said its possible we could be seeing the early stages of that now.

Dr. Young reiterates that the best way to keep yourself protected from these rising cases is social distancing, good hygiene practices, and getting boosted if you havent done so already.

See the original post:

Coronavirus cases on the rise once again - KAMR - MyHighPlains.com

COVID-19s 6th wave begins, with more seriously ill and more deaths – The Jerusalem Post

June 28, 2022

This website is using a security service to protect itself from online attacks. The action you just performed triggered the security solution. There are several actions that could trigger this block including submitting a certain word or phrase, a SQL command or malformed data.

Read the rest here:

COVID-19s 6th wave begins, with more seriously ill and more deaths - The Jerusalem Post

Top NY Doctor: New COVID Wave Is Starting, With the Worst Version’ of Omicron – NBC New York

June 28, 2022

A new COVID wave appears to be starting in New York City, fueled by the strongest subvariant of the omicron strain of coronavirus to date, one of the city's top epidemiologists said Tuesday.

The BA.5 subvariant, first seen in South Africa and then Portugal, is considered by some experts to be the "worst version" of omicron seen yet, given its apparent capacity to escape prior immunity and transmit more readily.

Dr. Jay Varma, a Weill Cornell epidemiologist and formerly then-mayor Bill de Blasio's top public health advisor during the pandemic, said infections appear to have stabilized at a high level in the city, rather than dropping.

"The decline of reported #COVID19 cases in NYC has stopped. Reported cases are at a high plateau, which means actual transmission is very high when you account for the >20x under-counting. This is likely the beginning of a BA.5 wave," Varma tweeted.

Transmission rates in the city hit two-month lows last week, but have started to tick up since then. The health department's own testing says BA.5 accounts for 17% of infections, but that data is almost two weeks old now. Nationally, CDC data pegs BA.5 at nearly 37% of cases.

"Experience from other countries means there will be another big increase in NYC #COVID19 infections, including among those who have had #Omicron in past few months," Varma went on to add.

He did note that it's still unclear what a BA.5 wave would mean for hospitalizations and deaths. Citywide COVID hospitalizations and deaths have been falling steadily and are at two-month lows.

The question now, he said, is whether boosters that worked against the BA.1 subvariant six months ago will have any effect against BA.5.

Read the original post:

Top NY Doctor: New COVID Wave Is Starting, With the Worst Version' of Omicron - NBC New York

Page 338«..1020..337338339340..350360..»